Newamsterdam Pharma Company Nv (NAMS)

Überblick Nachrichten Preisverlauf Financials Warum fällt NAMS? Forum Prognose

Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31
Periodenlänge	3 Monate
Revenues
Operating Expenses
Benefits Costs and Expenses
Costs And Expenses
Operating Income/Loss
Income/Loss From Continuing Operations Before Tax
Income/Loss From Continuing Operations After Tax
Net Income/Loss
Preferred Stock Dividends And Other Adjustments
Attributable To Noncontrolling Interest
Basic Average Shares
Diluted Average Shares
Basic Earnings Per Share
Diluted Earnings Per Share
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic

BMRN

$70.49

2.14%

SMMT

$18.50

2.83%

UTHR

$304.42

4.23%

RPRX

$32.46

0.89%

BNTX

$98.39

6.61%

ONC

$245.71

1.26%